🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

RecruitingNAAges 18 Years - 80 YearsAllBeijing Chao Yang Hospital
NCT05202314 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with obstruction are associated with worse oncologic outcomes compared with those having nonobstructive tumors. Conventionally, patients with malignant large bowel obstruction receive emergency surgery, with morbidity rates of 30%-60% and mortality rates of 7-22%, and about two-thirds of such patients end up with a permanent stoma. Self-expanding metallic stents (SEMS) haven been used as a bridge to surgery (to relieve obstruction prior to elective surgery) in patients with potentially resectable colorectal cancer. Several clinical trials demonstrate that SEMS as a bridge to surgery may be superior to emergency surgery considering the short-term outcomes. SEMS is associated with lower morbidity and mortality rate, increased primary anastomosis rate, and decreased stoma creation rate. Although about half of patients can achieve primary anastomosis after stent placement, the prima

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma * Able to give written, informed consent * Primary tumor was resectable * ECOG score 0 or 1 * Haemoglobin greater than 100 g/L after transfusion before chemotherapy, * White blood cells greater than 3.0×10# /L * Platelets greater than 100×10# / L; * Glomerular filtration rate greater than 50 mL per minute as calculated by the Wright or Cockroft formula * Bilirubin less than 1.5×Upper Limit of Normal(ULN) * ALT and AST less than 2.5×ULN Exclusion Criteria: * Distal rectal cancers(equal or less than 10cm from the anal verge) * Patients with signs of peritonitis and/or bowel perforation * Patients who did not give informed consent * Patients who were considered unfit for operative treatment or refuse surgery. * Patients with suspected or proven metastatic adenocarcinoma; * Patients with unresectable colorectal cancer, or planning for palliative treatment.
💊

What it tests

  • Immunotherapy (Camrelizumab)
📍

Where

1 site
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy